Trials / Completed
CompletedNCT01837095
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Polyphor Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin. Different doses and dosing frequencies will be investigated
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | POL6326 | POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2013-04-22
- Last updated
- 2018-09-14
Locations
12 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT01837095. Inclusion in this directory is not an endorsement.